Table 2.

Baseline characteristics of the patients enrolled in the cohorts. Training and testing groups are characterized by mean ± standard derivation (SD) and range from minimal to maximal value or as categorical, if applicable

Patients’ parameters [N]*	Study Cohort (Training set) N = 46	Test Cohort (Testing set) N = 12
Gender [men/women]	8/38	2/10
Age at biopsy [years]	35.50 ± 14.06	38.17 ± 14.06
LN class II/III/IV/V/VI	1/10/21/9/5	0/2/4/3/3
Number of glomeruli in specimen	20.83 ± 10.21	18.08 ± 6.26
Number of totally sclerotic glomeruli	1.61 ± 3.08	2.92 ± 4.68
Number of partially sclerotic glomeruli	3.95 ± 7.79	3.25 ± 3.93
Number of cellular/cellular-fibrotic crescents	1.43 ± 3.07	0.50 ± 1.45
Number of glomeruli with fibrillary necrosis	2.52 ± 4.85	1.58 ± 2.07
Number of glomeruli without changes	1.09 ± 2.50	0.25 ± 0.87
Activity Index	8.99 ± 4.77	8.83 ± 3.51
Chronicity Index	2.95 ± 1.91	3.92 ± 2.78
Interstitial fibrosis [%]	9.02 ± 5.74	13.33 ± 10.73
WBC [10^3/ul]	8.09 ± 3.26	7.34 ± 1.81
NEU [10^3/ul]	5.49 ± 2.61	5.60 ± 2.09
LYM [10^3/ul]	1.90 ± 0.95	1.28 ± 0.71
NLR	3.90 ± 4.06	6.42 ± 5.05
HGB [g/dl]	12.06 ± 1.82	11.26 ± 1.19
PLT [10^3/ul]	238.35 ± 79.15	197.92 ± 70.78
PLR	176.80 ± 147.66	219.48 ± 132.10
ERS [mm/1 h]	37.75 ± 24.92	28.27 ± 15.11
CRP [mg/dl]	4.59 ± 8.67	2.16 ± 2.70
sCr [mg/dl]	1.27 ± 0.69	1.32 ± 0.48
eGFR [ml/min/1.73 m2]	67.98 ± 26.65	57.08 ± 26.05
TP [g/dl]	5.35 ± 0.95	5.23 ± 0.89
Albumin [g/dl]	2.87 ± 0.58	2.82 ± 0.52
Total Cholesterol [mg/dl]	274.77 ± 80.20	243.48 ± 89.49
Triglycerides [mg/dl]	202.75 ± 114.55	171.70 ± 68.39
C3 [g/l]	0.86 ± 0.29	0.76 ± 0.29
C4 [g/l]	0.18 ± 0.09	0.16 ± 0.12
ANA (0/1/undefined)	1/39/6	2/9/1
Erythrocyturia [RBC/HPF]	10/19/17	3/4/5
UPCR [mg/mg]	2.91 ± 2.12	4.76 ± 4.83
Target - CR [1/0]	14/32	4/8